Cytotoxic edema in a patient with neuromyelitis optica: This may be suggestive of various pathogenic roles of NMO-IgG

Cytotoxic edema in a patient with neuromyelitis optica: This may be suggestive of various pathogenic roles of NMO-IgG

Bibliografski detalji
Glavni autori:	Min, J, Kim, B, Waters, P, Vincent, A, Lee, K
Format:	Conference item
Izdano:	2010

Slični predmeti

NMO-IgG in the diagnosis of neuromyelitis optica.
od: Jarius, S, i dr.
Izdano: (2007)

An audit of the diagnostic usefulness of the NMO-IgG assay for neuromyelitis optica
od: Littleton, E, i dr.
Izdano: (2006)

Revised diagnostic criteria for neuromyelitis optica--incorporation of NMO-IgG status.
od: Jarius, S, i dr.
Izdano: (2007)

Devic's neuromyelitis optica: Prognostic implications of NMO IgG status in Turkish patients
od: Akman-Demir, G, i dr.
Izdano: (2008)

Frequency of Aqp4-Ab in patients with neuromyelitis optica (Devic's syndrome) is higher than predicted by NMO-IgG testing
od: Jarius, S, i dr.
Izdano: (2007)

Neuromyelitis optica IgG causes placental inflammation and fetal death.
od: Saadoun, S, i dr.
Izdano: (2013)

Neuromyelitis optica IgG causes placental inflammation and fetal death in mice
od: Saadoun, S, i dr.
Izdano: (2013)

Effect of IgG from seronegative and seropositive neuromyelitis optica patients on mouse brain
od: Saadoun, S, i dr.
Izdano: (2013)

Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica.
od: Kim, S, i dr.
Izdano: (2011)

NMO-IgG/Aqp4-Ab belongs to the IgG1 subclass and activates complement in vitro
od: Jarius, S, i dr.
Izdano: (2007)

IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica
od: Jacob, S, i dr.
Izdano: (2008)

MOG-IGG IN NMO AND NMO-LIKE DISORDERS
od: Luppe, S, i dr.
Izdano: (2014)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
od: Downer, J, i dr.
Izdano: (2012)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: Is MRI obsolete?
od: Downer, J, i dr.
Izdano: (2012)

IgG subclasses of disease-specific antibodies and complement activation in vitro in myasthenia gravis and neuromyelitis optica
od: Jacob, S, i dr.
Izdano: (2007)

A novel sensitive assay for aqueporin-4 antibodies (NMO-IgG)
od: Waters, P, i dr.
Izdano: (2007)

Neutrophil protease inhibition reduces NMO-IgG-induced damage in mouse brain
od: Papadopoulos, M, i dr.
Izdano: (2011)

LONG TERM OUTCOME IN NEUROMYELITIS OPTICA: LESSONS FROM 6 YEARS OF THE UK NMO STUDY
od: Jacob, A, i dr.
Izdano: (2009)

Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays.
od: Waters, P, i dr.
Izdano: (2012)

Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes
od: Juryńczyk, M, i dr.
Izdano: (2015)

T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement.
od: Saadoun, S, i dr.
Izdano: (2011)

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.
od: Saadoun, S, i dr.
Izdano: (2010)

Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO.
od: Min, J, i dr.
Izdano: (2012)

Spinal cord MRI features in neuromyelitis optica (NMO): characteristics and relationship with severity and recovery in longitudinally extensive transverse myelitis (LETM) attacks
od: Murchison, A, i dr.
Izdano: (2013)

Complement activation in patients with neuromyelitis optica
od: Nytrova, P, i dr.
Izdano: (2014)

Complement activation in patients with neuromyelitis optica.
od: Nytrova, P, i dr.
Izdano: (2014)

The borderland of neuromyelitis optica.
od: Matthews, L, i dr.
Izdano: (2009)

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, i dr.
Izdano: (2015)

The evolving clinical spectrum of neuromyelitis optica
od: Viegas, S, i dr.
Izdano: (2008)

Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
od: Collongues, N, i dr.
Izdano: (2013)

Use of mitoxantrone in neuromyelitis optica.
od: Kitley, J, i dr.
Izdano: (2011)

TREATMENT OF NEUROMYELITIS OPTICA WITH AZATHIOPRINE
od: Elsone, L, i dr.
Izdano: (2012)

Symptomatic brain involvement as the initial manifestation of neuromyelitis optica.
od: Min, J, i dr.
Izdano: (2013)

Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica.
od: Viegas, S, i dr.
Izdano: (2009)

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
od: Jarius, S, i dr.
Izdano: (2008)

Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays.
od: Waters, P, i dr.
Izdano: (2008)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
od: Kitley, J, i dr.
Izdano: (2012)

Deteksi IgG
od: , SUHARTI, Netti, i dr.
Izdano: (2001)

IgG4 autoantibodies and autoantigens in the context of IgG4-autoimmune disease and IgG4-related disease
od: Motta, RV, i dr.
Izdano: (2024)

Neuromyelitis optica in patients with gluten sensitivity associated with antibodies to aquaporin-4.
od: Jarius, S, i dr.
Izdano: (2008)